EA200400991A1 - Фармацевтические композиции, содержащие ингибиторы протеазы вируса гепатита c - Google Patents
Фармацевтические композиции, содержащие ингибиторы протеазы вируса гепатита cInfo
- Publication number
- EA200400991A1 EA200400991A1 EA200400991A EA200400991A EA200400991A1 EA 200400991 A1 EA200400991 A1 EA 200400991A1 EA 200400991 A EA200400991 A EA 200400991A EA 200400991 A EA200400991 A EA 200400991A EA 200400991 A1 EA200400991 A1 EA 200400991A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- virus
- hepatitis
- pharmaceutical compositions
- compositions containing
- containing inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
В заявке описаны фармацевтические композиции ингибиторов протеазы вируса гепатита C, обладающие повышенной биологической доступностью, и способы применения этих композиций для ингибирования репликации вируса гепатита C (HCV) и лечения инфекции, вызываемой HCV. Указанные композиции включают системы на основе сорастворителей, системы на основе липидов, твердые дисперсии и гранулы, и все они содержат ингибитор протеазы вируса гепатита C, по меньшей мере один фармацевтически приемлемый амин и необязательно один или несколько дополнительных ингредиентов.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35569402P | 2002-02-07 | 2002-02-07 | |
PCT/US2003/003380 WO2003066103A1 (en) | 2002-02-07 | 2003-02-05 | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200400991A1 true EA200400991A1 (ru) | 2005-02-24 |
Family
ID=27734548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200400991A EA200400991A1 (ru) | 2002-02-07 | 2003-02-05 | Фармацевтические композиции, содержащие ингибиторы протеазы вируса гепатита c |
Country Status (25)
Country | Link |
---|---|
US (1) | US6828301B2 (ru) |
EP (1) | EP1474172B1 (ru) |
JP (1) | JP2005518423A (ru) |
KR (1) | KR20040089605A (ru) |
CN (1) | CN1627959A (ru) |
AR (1) | AR038823A1 (ru) |
AT (1) | ATE344056T1 (ru) |
AU (1) | AU2003208989A1 (ru) |
BR (1) | BR0307524A (ru) |
CA (1) | CA2472249A1 (ru) |
CO (1) | CO5611167A2 (ru) |
DE (1) | DE60309433T2 (ru) |
EA (1) | EA200400991A1 (ru) |
EC (1) | ECSP045223A (ru) |
ES (1) | ES2276045T3 (ru) |
HR (1) | HRP20040720A2 (ru) |
IL (1) | IL162673A0 (ru) |
MX (1) | MXPA04007699A (ru) |
NO (1) | NO20043722L (ru) |
PE (1) | PE20030865A1 (ru) |
PL (1) | PL371287A1 (ru) |
TW (1) | TW200302734A (ru) |
UY (1) | UY27650A1 (ru) |
WO (1) | WO2003066103A1 (ru) |
ZA (1) | ZA200405064B (ru) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2263687T3 (es) | 2000-11-20 | 2006-12-16 | Bristol-Myers Squibb Company | Inhibidores tripeptidicos de la hepatitis c. |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
AU2003301959A1 (en) | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
PL215228B1 (pl) | 2002-05-20 | 2013-11-29 | Bristol Myers Squibb Co | Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie |
PL211889B1 (pl) | 2002-05-20 | 2012-07-31 | Bristol Myers Squibb Co | Pochodna heterocyklosulfonamidowa, kompozycja ją zawierająca oraz ich zastosowanie |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20040033959A1 (en) * | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
US20040138109A1 (en) * | 2002-09-30 | 2004-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Potent inhibitor of HCV serine protease |
US20050159345A1 (en) * | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
KR20050108420A (ko) * | 2003-04-02 | 2005-11-16 | 베링거 인겔하임 인터내셔날 게엠베하 | C형 간염 바이러스 프로테아제 억제제를 위한 약제학적조성물 |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
PE20050431A1 (es) * | 2003-09-22 | 2005-07-19 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c |
TWI375679B (en) * | 2003-10-14 | 2012-11-01 | Hoffmann La Roche | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1687021B1 (en) | 2003-11-20 | 2013-11-06 | Boehringer Ingelheim International GmbH | Method of removing transition metals, especially from metathesis reaction products |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1730167B1 (en) * | 2004-01-21 | 2011-01-12 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
ES2336009T3 (es) | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
NZ549697A (en) * | 2004-03-30 | 2009-12-24 | Intermune Inc | Macrocyclic compounds as inhibitors of viral replication |
JP2008501802A (ja) * | 2004-06-08 | 2008-01-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 医薬組成物 |
AU2005274700B2 (en) * | 2004-07-16 | 2011-11-10 | Gilead Sciences, Inc. | Antiviral compounds |
WO2007001406A2 (en) * | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
CA2583152A1 (en) * | 2004-10-21 | 2006-04-27 | Pfizer Inc. | Inhibitors of hepatitis c virus protease, and compositions and treatments using the same |
US20060088591A1 (en) * | 2004-10-22 | 2006-04-27 | Jinghua Yuan | Tablets from a poorly compressible substance |
JP2008518931A (ja) * | 2004-10-29 | 2008-06-05 | ノバルティス アクチエンゲゼルシャフト | 自発的に分散可能な医薬組成物 |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20060240051A1 (en) * | 2005-04-26 | 2006-10-26 | Singleton Andy H | Eutectic blends containing a water soluble vitamin derivative |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2007015270A (es) * | 2005-06-02 | 2008-02-21 | Schering Corp | Combinacion de inhibidores de proteasa de virus de la hepatitis c con un agente tensioactivo. |
PL1891089T3 (pl) | 2005-06-02 | 2015-05-29 | Merck Sharp & Dohme | Inhibitory proteazy HCV w połączeniu z pokarmem |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
NZ594105A (en) | 2005-07-25 | 2013-02-22 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
WO2007030492A2 (en) * | 2005-09-06 | 2007-03-15 | Guilford F Timothy | Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione |
ATE493409T1 (de) | 2005-10-11 | 2011-01-15 | Intermune Inc | Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
CA2656356C (en) * | 2006-07-07 | 2013-04-09 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2686546A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
AU2008271116B2 (en) | 2007-06-29 | 2012-09-20 | Gilead Sciences, Inc. | Antiviral compounds |
CN101801925A (zh) | 2007-06-29 | 2010-08-11 | 吉里德科学公司 | 抗病毒组合物 |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
MX2010008523A (es) | 2008-02-04 | 2010-08-31 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa. |
SG175692A1 (en) | 2008-04-15 | 2011-11-28 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102046648A (zh) | 2008-05-29 | 2011-05-04 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN101744823B (zh) * | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
EP2451438B8 (en) * | 2009-07-07 | 2014-04-09 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
AR077712A1 (es) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | Inhibidores de serina proteasa macrociclica |
CN102822175A (zh) | 2009-12-18 | 2012-12-12 | 埃迪尼克斯医药公司 | 5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂 |
WO2011112558A2 (en) * | 2010-03-10 | 2011-09-15 | Abbott Laboratories | Solid compositions |
JP5902189B2 (ja) | 2010-11-18 | 2016-04-13 | メタリシス リミテッド | 電解装置 |
US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
BR112013016480A2 (pt) | 2010-12-30 | 2016-09-20 | Abbvie Inc | macrocíclo da fenantridina inibadores da protease da serina da hepatite c |
TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途 |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US8957203B2 (en) * | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US20130302414A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI65914C (fi) | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
US5071643A (en) | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
IL102236A0 (en) | 1991-06-27 | 1993-01-14 | Ltt Inst Co Ltd | Topical preparations containing cyclosporin |
GB9208712D0 (en) | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
US5376688A (en) | 1992-12-18 | 1994-12-27 | R. P. Scherer Corporation | Enhanced solubility pharmaceutical solutions |
WO1996036316A1 (en) | 1995-05-19 | 1996-11-21 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
BR9810729B1 (pt) | 1997-07-29 | 2010-07-13 | composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante. | |
ES2174462T3 (es) | 1997-07-29 | 2002-11-01 | Upjohn Co | Formulacion autoestimulante para compuestos lipofilos. |
US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
-
2003
- 2003-02-04 US US10/357,919 patent/US6828301B2/en not_active Expired - Lifetime
- 2003-02-05 MX MXPA04007699A patent/MXPA04007699A/es not_active Application Discontinuation
- 2003-02-05 PE PE2003000135A patent/PE20030865A1/es not_active Application Discontinuation
- 2003-02-05 AT AT03707713T patent/ATE344056T1/de not_active IP Right Cessation
- 2003-02-05 CA CA002472249A patent/CA2472249A1/en not_active Abandoned
- 2003-02-05 CN CNA03803395XA patent/CN1627959A/zh active Pending
- 2003-02-05 WO PCT/US2003/003380 patent/WO2003066103A1/en active IP Right Grant
- 2003-02-05 DE DE60309433T patent/DE60309433T2/de not_active Expired - Fee Related
- 2003-02-05 EP EP03707713A patent/EP1474172B1/en not_active Expired - Lifetime
- 2003-02-05 AU AU2003208989A patent/AU2003208989A1/en not_active Abandoned
- 2003-02-05 JP JP2003565526A patent/JP2005518423A/ja active Pending
- 2003-02-05 KR KR10-2004-7012235A patent/KR20040089605A/ko not_active Application Discontinuation
- 2003-02-05 ES ES03707713T patent/ES2276045T3/es not_active Expired - Lifetime
- 2003-02-05 IL IL16267303A patent/IL162673A0/xx unknown
- 2003-02-05 UY UY27650A patent/UY27650A1/es not_active Application Discontinuation
- 2003-02-05 PL PL03371287A patent/PL371287A1/xx not_active Application Discontinuation
- 2003-02-05 EA EA200400991A patent/EA200400991A1/ru unknown
- 2003-02-05 BR BR0307524-9A patent/BR0307524A/pt active Pending
- 2003-02-06 TW TW092102382A patent/TW200302734A/zh unknown
- 2003-02-07 AR ARP030100386A patent/AR038823A1/es not_active Suspension/Interruption
-
2004
- 2004-06-25 ZA ZA200405064A patent/ZA200405064B/en unknown
- 2004-08-06 EC EC2004005223A patent/ECSP045223A/es unknown
- 2004-08-06 HR HR20040720A patent/HRP20040720A2/hr not_active Application Discontinuation
- 2004-09-06 NO NO20043722A patent/NO20043722L/no not_active Application Discontinuation
- 2004-09-07 CO CO04088288A patent/CO5611167A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20030195228A1 (en) | 2003-10-16 |
CO5611167A2 (es) | 2006-02-28 |
EP1474172B1 (en) | 2006-11-02 |
CA2472249A1 (en) | 2003-08-14 |
NO20043722L (no) | 2004-09-06 |
UY27650A1 (es) | 2003-09-30 |
MXPA04007699A (es) | 2004-11-10 |
PE20030865A1 (es) | 2003-11-26 |
AU2003208989A1 (en) | 2003-09-02 |
CN1627959A (zh) | 2005-06-15 |
JP2005518423A (ja) | 2005-06-23 |
EP1474172A1 (en) | 2004-11-10 |
IL162673A0 (en) | 2005-11-20 |
ECSP045223A (es) | 2004-09-28 |
PL371287A1 (en) | 2005-06-13 |
AR038823A1 (es) | 2005-01-26 |
ES2276045T3 (es) | 2007-06-16 |
HRP20040720A2 (en) | 2005-04-30 |
US6828301B2 (en) | 2004-12-07 |
KR20040089605A (ko) | 2004-10-21 |
ATE344056T1 (de) | 2006-11-15 |
DE60309433T2 (de) | 2007-05-03 |
ZA200405064B (en) | 2005-05-30 |
TW200302734A (en) | 2003-08-16 |
WO2003066103A1 (en) | 2003-08-14 |
BR0307524A (pt) | 2004-12-21 |
DE60309433D1 (de) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200400991A1 (ru) | Фармацевтические композиции, содержащие ингибиторы протеазы вируса гепатита c | |
EA200501532A1 (ru) | Фармацевтические композиции ингибиторов вирусной протеазы гепатита с | |
ATE481106T1 (de) | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer | |
ES2240446T3 (es) | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. | |
TWI265927B (en) | Novel compounds as NS3-serine protease inhibitors of hepatitis C virus | |
NO20044897L (no) | Hepatitt C virus inhibitorer | |
MY140710A (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
ATE413411T1 (de) | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren | |
MXPA03000627A (es) | Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c. | |
EA200100992A1 (ru) | Ингибиторы фермента impdh | |
CL2004001161A1 (es) | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. | |
ATE327246T1 (de) | Hepatitis c tripeptid inhibitoren | |
EA200400987A1 (ru) | Трипептиды, несущие простой гидроксипролиновый эфир замещённого хинолина, предназначенные для ингибирования протеазы ns3 (гепатит c) | |
CY1111212T1 (el) | Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ | |
MX2007004783A (es) | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. | |
TW200518746A (en) | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease | |
EA200500406A1 (ru) | Активный ингибитор серинпротеазы hcv | |
EA200900184A1 (ru) | 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации | |
EA200400886A1 (ru) | Макроциклические пептиды, обладающие активностью в отношении вируса гепатита c | |
EA200800178A1 (ru) | Ингибиторы вируса гепатита с (hcv) | |
MXPA03000626A (es) | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c. | |
EA200600227A1 (ru) | Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов | |
EA200400690A1 (ru) | Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз |